Condition (MeSH)
Synkinesis
ClinicalTrials.gov lists 10 trials for Synkinesis or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
10 of the 10 trials are tagged with Synkinesis itself; the rest are tagged with a narrower condition beneath it.
When did Synkinesis trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2012 | 1 |
| 2004 | 1 |
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Synkinesis trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 4 |
| Not applicable | 4 |
| Observational | 1 |
How many Synkinesis trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 1 |
| Completed | 4 |
| Withdrawn | 1 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which drugs are being tested for Synkinesis? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Apraclonidine | 1 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| type A botulinum toxin | 2 |
| AbobotulinumtoxinA Injectable Product | 1 |
| Incobotulinumtoxin A Injectable Product | 1 |
| Chemodenervation (4 months) | 1 |
| OnabotulinumtoxinA Injectable Product | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Synkinesis? (16)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Bilateral muscle activation in postparalytic facial synkinesis: a cross-sectional high-resolution surface electromyography study. | Scientific reports | 2026 | Yes |
| Synchronous surface electromyography as objective method to evaluate the outcome of a biofeedback training in patients with facial synkinesis. | Scientific reports | 2025 | Yes |
| Effects of Kabat rehabilitation versus mime therapy on facial disability and synkinesis in patients of Bell's palsy. | JPMA. The Journal of the Pakistan Medical Association | 2024 | Yes |
| Masseteric-zygomatic nerve transfer for the management of eye closure-smile excursion synkinesis. | American journal of otolaryngology | 2020 | Yes |
| Decreased ACKR3 (CXCR7) function causes oculomotor synkinesis in mice and humans. | Human molecular genetics | 2019 | Yes |
Showing 5 of 16 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.